FDA approves second interchangeable insulin product, Rezvoglar

The US Food and Drug Administration has approved the second interchangeable biosimilar insulin product to Lantus (insulin glargine), Eli Lilly’s (NYSE: LLY) Rezvoglar (insulin glargine-aglr).

Rezvoglaris a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

The FDA previously approved Rezvoglar as a biosimilar to Lantus, which is marketed by Sanofi (Euronext: SAN), in December 2021. A biosimilar is a biological product (biologic) that is highly similar to and has no clinically-meaningful differences from an existing FDA-approved biologic, called a reference product.